As such, CD200 has a direct and significant suppressive influence on NK cell activity in AML patients and may contribute to the increased relapse rate in CD200+ patients, and therefore the CD200R is an attractive target to block, particularly for tumors with high CD200 expression [89]. Here, CD200 is linked to acute myeloid leukemia.